CoChat

PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer

Published version of a preprint

The DOI matches its Crossref record; 38 of the 40 references it cites were found in a registry or an index.

Abstract

Abstract Purpose: Tumor-associated PD-L1 expression is predictive of clinical response to PD-1–directed immunotherapy. However, PD-L1–negative patients may also respond to PD-1 checkpoint blockade, suggesting that other PD-1 ligands may be relevant to the clinical activity of these therapies. The prevalence of PD-L2, the other known ligand of PD-1, and its relationship to response to anti-PD-1 therapy were evaluated. Experimental Design: PD-L2 expression was assessed in archival tumor tissue from seven indications using a novel immunohistochemical assay. In addition, relationships between clinical response and PD-L2 status were evaluated in tumor tissues from patients with head and neck squamous cell carcinoma (HNSCC) with recurrent or metastatic disease, treated with pembrolizumab. Results: PD-L2 expression was observed in all tumor types and present in stromal, tumor, and endothelial cells. The prevalence and distribution of PD-L2 correlated significantly with PD-L1 (P = 0.0012–<0.0001); however, PD-L2 was detected in the absence of PD-L1 in some tumor types. Both PD-L1 and PD-L2 positivity significantly predicted clinical response to pembrolizumab on combined tumor, stromal and immune cells, with PD-L2 predictive independent of PD-L1. Response was greater in patients positive for both PD-L1 and PD-L2 (27.5%) than those positive only for PD-L1 (11.4%). PD-L2 status was also a significant predictor of progression-free survival (PFS) with pembrolizumab independent of PD-L1 status. Longer median times for PFS and overall survival were observed for PD-L2–positive than PD-L2–negative patients. Conclusions: Clinical response to pembrolizumab in patients with HNSCC may be related partly to blockade of PD-1/PD-L2 interactions. Therapy targeting both PD-1 ligands may provide clinical benefit in these patients. Clin Cancer Res; 23(12); 3158–67. ©2017 AACR.

Overview

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-16-1761

Cites

38 of 38 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 38 references

Research works printed but not linked: 3

  1. Merck & Co, 2015, Keytruda (pembrolizumab) prescribing information
  2. Bristol-Meyers Squibb, 2016, OPDIVO (nivolumab) prescribing information
  3. Genentech, 2016, TECENTRIQ (atezolizumab)

Cited by

See all 655

Metadata

Authors
Yearley, J. H., Gibson, C., Yu, N., Moon, C., Murphy, E., Juco, J., Lunceford, J., Cheng, J., Chow, L. Q. M., Seiwert, T. Y., Handa, M., Tomassini, J. E., & McClanahan, T.
Affiliations
  • Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
  • University of Pennsylvania (US)
  • University of Washington (US)
  • University of Chicago (US)
Corresponding author
Yearley, Jennifer H.
Venue
Clinical Cancer Research
Published
2017-06-14
Volume
23
Issue
12
Pages
3158-3167
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2626773261
Cited by
594
References
40
Citations by year
2026: 29 · 2025: 41 · 2024: 76 · 2023: 56 · 2022: 84 · 2021: 80 · 2020: 82 · 2019: 63 · 2018: 53 · 2017: 24
FWCI
26.76
Type
journal article
Language
en
Open access
closed
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
PD-L2, pembrolizumab, head and neck squamous cell carcinoma, anti-PD-1 therapy, PD-L1, predictive biomarkers, immune checkpoint blockade, tumor immune microenvironment, progression-free survival, overall survival
MeSH terms
Squamous Cell Carcinoma of Head and Neck, Adult, Aged, Aged, 80 and over, Carcinoma, Squamous Cell, Female, Head and Neck Neoplasms, Humans, Immunotherapy, Male, Middle Aged, Gene Expression Regulation, Neoplastic, Disease-Free Survival, Programmed Cell Death 1 Receptor, Programmed Cell Death 1 Ligand 2 Protein, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-16-1761
The paper
Yearley, J. H., Gibson, C., Yu, N., Moon, C., Murphy, E., Juco, J., Lunceford, J., Cheng, J., Chow, L. Q. M., Seiwert, T. Y., Handa, M., Tomassini, J. E., & McClanahan, T. (2017). PD-L2 Expression in Human Tumors: Relevance to Anti-PD-1 Therapy in Cancer. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-16-1761

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.